Gary Remington, MD, PhD

Effects of Long-Term Valbenazine on Psychiatric Status in Patients With Tardive Dyskinesia and a Primary Mood Disorder

Objective: In two long-term phase 3 studies, sustained TD improvements were observed in participants who received once-daily treatment with valbenazine (40 or 80 mg). Data from these stud...

Joshua Burke , MS;

Scott Siegert , PharmD;

Gary Remington , MD, PhD;

Rachel Weber , PhD;

Leslie Lundt , MD;

Khodayar Farahmand , PharmD;

Christoph U. Correll , MD;

Roger McIntyre , MD, FRCPC;

03/01/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8 ⁠–⁠ November 10

November 8

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Gary Remington, MD, PhD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products